Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort (Q27853282)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Marie Wislez

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Federico Cappuzzo

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Alexis B Cortot

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Denis Moro-Sibilot

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

J Mazières

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

F Barlesi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

B Besse

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

I Monnet

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

M Beau-Faller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

S Peters

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

E Dansin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

M Früh

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

M Pless

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

R Rosell

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

P Fournel

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

V Westeel

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Milia

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

O Gautschi

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

1 reference

February 2016

0 references

published in

Annals of Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

281-286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26598547%20AND%20SRC:MED&resulttype=core&format=json

Management of non-small-cell lung cancer: recent developments

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV573